Trial Profile

A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trabedersen (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Adenocarcinoma; Pancreatic cancer
Focus Registrational; Therapeutic Use
Acronyms STOP-PC
Sponsors Mateon Therapeutics; Oncotelic Therapeutics

13 Mar 2024 Planned number of patients changed from 468 to 455.
13 Mar 2024 Planned initiation date changed from 1 Dec 2023 to 1 May 2024.
04 Mar 2024 Status changed from not yet recruiting to recruiting, according to an Oncotelic Therapeutics media release. The company invites participation in this STOP-PC clinical trial which is now open for recruitment.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com